[1] The Global Use of Medicine in 2019 and Outlook to 2023[EB/OL]. in 2019 and Outlook to 2023[EB/OL]. [2021-03-10]. https://www.iqvia.com/insights/the-iqvia-institute/reports/the-global-use-of-medicine-in-2019-and-outlook-to-2023. [2] Sun J, Zhu XH, Wang S, et al.Overview of targeted antitumor drugs approved by FDA in recent five years[J].Chinese Journal of New Drugs(中国新药杂志), 2016, 25(1): 1-6. [3] Chen WY, Weng WM, Jing LY, et al.Lipitor is approved as first-line and maintenance treatment for advanced non squamous non-small cell lung cancer[J]. China Oncology(中国癌症杂志), 2014, 24(8): 614. [4] Liu YJ, Tian PW.Progress of bevacizumab in malignant pleural effusion caused by non-small cell lung cancer[J]. Chinese Journal of Lung Cancer(中国肺癌杂志), 2019, 22(2): 118-124. [5] Gao DQ, Wang JL.Current status of research on risk factors of lung cancer[J]. Chinese Journal of Cancer Prevention and Treatment(中华肿瘤防治杂志), 2019, 26(21): 1657-1662. [6] Xiu PT, Xin ML, Liu H.Meta-analysis of safety and efficacy of antiangiogenic drug aflibercept for metastatic colorectal cancer[J]. World Chinese Journal of Digestology(世界华人消化杂志), 2020, 28(1): 18-25. [7] Lai SQ, Wang QW, Liu JH.Analysis of the approved new drugs and drug registration applications in China in 2017[J]. Chinese Journal of Pharmaceuticals(中国医药工业杂志), 2018, 49(3): 392-396. [8] Zou XN, Zhao P.Analysis of cancer situation in China in 70 years[J].Chinese Journal of Clinical Oncology and Rehabilitation(中国肿瘤临床与康复), 2019, 26(10): 1153-1161. [9] Martin EG, Shivaani K, Giuseppe G.Next generation oncology drug development: opportunities and challenges[J]. Nature Reviews Clinical Oncology, 2009, 6(5): 259-265. [10] Guo ZH, Cao XT.The current situation and prospect of immunocyte-therapy for tumor[J]. Chinese Journal of Cancer Biotherapy(中国肿瘤生物治疗杂志), 2016, 23(2): 149-160. [11] Dobbelstein M, Moll U.Targeting tumour-supportive cellular machineries in anticancer drug development[J]. Nature Reviews. Drug discovery, 2014, 13(3): 179-196. [12] Zhang Y, Dhruba K, Sun HR, et al.Research progresses in molecular targeted therapy of cancer[J]. Fudan University Journal of Medical Sciences(复旦学报(医学版)), 2016, 43(1): 115-121. [13] Tian H, Xiao GZ, Liu Y G.Market analysis on antitumor drugs[J]. Drugs & Clinic(现代药物与临床), 2013, 28(3): 424-427. [14] Zhang L, Pang PS, Yu L, et al.Study on EU R&D scoreboard and its inspiration to China[J]. Scientific Management Research(科学管理研究), 2021, 39(1): 142-147. |